Abstract:Viruses are obligate intracellular parasites and therefore their replication completely depends on host cell factors. In case of the hepatitis C virus (HCV), a positive-strand RNA virus that in the majority of infections establishes persistence, cyclophilins are considered to play an important role in RNA replication. Subsequent to the observation that cyclosporines, known to sequester cyclophilins by direct binding, profoundly block HCV replication in cultured human hepatoma cells, conflicting results were obtained as to the particular cyclophilin (Cyp) required for viral RNA replication and the underlying possible mode of action. By using a set of cell lines with stable knock-down of CypA or CypB, we demonstrate in the present work that replication of subgenomic HCV replicons of different genotypes is reduced by CypA depletion up to 1,000-fold whereas knock-down of CypB had no effect. Inhibition of replication was rescued by over-expression of wild type CypA, but not by a mutant lacking isomerase activity. Replication of JFH1-derived full length genomes was even more sensitive to CypA depletion as compared to subgenomic replicons and virus production was completely blocked. These results argue that CypA may target an additional viral factor outside of the minimal replicase contributing to RNA amplification and assembly, presumably nonstructural protein 2. By selecting for resistance against the cyclosporine analogue DEBIO-025 that targets CypA in a dose-dependent manner, we identified two mutations (V2440A and V2440L) close to the cleavage site between nonstructural protein 5A and the RNA-dependent RNA polymerase in nonstructural protein 5B that slow down cleavage kinetics at this site and reduce CypA dependence of viral replication. Further amino acid substitutions at the same cleavage site accelerating processing increase CypA dependence. Our results thus identify an unexpected correlation between HCV polyprotein processing and CypA dependence of HCV replication.

Cyclophilin A: a Potential Drug Target for AIDS Therapy

Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.

Cyclophilin A: a key player for etiological agent infection

Emerging role of cyclophilin A in HIV-1 infection: from producer cell to the target cell nucleus

Cyclophilin A Facilitates HIV-1 DNA Integration

Cyclophilin A: promising target in cancer therapy

Dual targeting inhibitors for HIV-1 capsid and cyclophilin A: molecular docking, molecular dynamics, and quantum mechanics

Discovering Novel Chemical Inhibitors of Human Cyclophilin A: Virtual Screening, Synthesis, and Bioassay

Discovery of a Potent Peptidic Cyclophilin A Inhibitor Trp-Gly-Pro

Spatiotemporal binding of cyclophilin A and CPSF6 to capsid regulates HIV-1 nuclear entry and integration

Strategies for Inhibiting Function of HIV-1 Accessory Proteins: A Necessary Route to AIDS Therapy?

Short Cyclic Peptides Derived from the C-terminal Sequence of Α1-Antitrypsin Exhibit Significant Anti-Hiv-1 Activity

The Role of Cyclophilins in Viral Infection and the Immune Response

Cyclic Peptide Inhibitors of HIV-1 Capsid-Human Lysyl-Trna Synthetase Interaction.

The Research of Anti-HIV Drugs Small Molecular CCR5 Antagonist

Inhibitors of Cyclophilin A: Current and Anticipated Pharmaceutical Agents for Inflammatory Diseases and Cancers

Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics

The Progress of Cyclophilin A in Cancer Research

Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID 19

Functions of cyclophilin A in atherosclerosis.

The effects of CypA on apoptosis: potential target for the treatment of diseases